106 related articles for article (PubMed ID: 35181219)
1. A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Adults With Diabetic Nephropathy.
Mohsen M; Elberry AA; Rabea AM; Khalil DM; Abdelrahim MEA; Hussein RRS
Can J Diabetes; 2022 Mar; 46(2):134-141.e2. PubMed ID: 35181219
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
[TBL] [Abstract][Full Text] [Related]
3. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
Mosenzon O; Leibowitz G; Bhatt DL; Cahn A; Hirshberg B; Wei C; Im K; Rozenberg A; Yanuv I; Stahre C; Ray KK; Iqbal N; Braunwald E; Scirica BM; Raz I
Diabetes Care; 2017 Jan; 40(1):69-76. PubMed ID: 27797925
[TBL] [Abstract][Full Text] [Related]
4. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.
Udell JA; Bhatt DL; Braunwald E; Cavender MA; Mosenzon O; Steg PG; Davidson JA; Nicolau JC; Corbalan R; Hirshberg B; Frederich R; Im K; Umez-Eronini AA; He P; McGuire DK; Leiter LA; Raz I; Scirica BM;
Diabetes Care; 2015 Apr; 38(4):696-705. PubMed ID: 25552421
[TBL] [Abstract][Full Text] [Related]
5. Saxagliptin and vildagliptin lowered albuminuria in patients with diabetes and hypertension independent on glycaemic control.
Mohsen M; Elberry AA; Mohamed Rabea A; Abdelrahim MEA; Hussein RRS
Int J Clin Pract; 2021 Mar; 75(3):e13769. PubMed ID: 33068301
[TBL] [Abstract][Full Text] [Related]
6. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
7. Associations of urinary, glomerular, and tubular markers with the development of diabetic kidney disease in type 2 diabetes patients.
Jiang X; Zhang Q; Wang HB; Cui XF; Liu R
J Clin Lab Anal; 2018 Jan; 32(1):. PubMed ID: 28236320
[TBL] [Abstract][Full Text] [Related]
8. Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Kim WJ; Jeon YK; Kim BH; Kwak IS; Lee EK; Kim YK
Diabetes Metab Res Rev; 2014 Nov; 30(8):736-41. PubMed ID: 24687388
[TBL] [Abstract][Full Text] [Related]
9. Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients.
Kim SS; Song SH; Kim IJ; Yang JY; Lee JG; Kwak IS; Kim YK
Diabetes Res Clin Pract; 2012 Aug; 97(2):251-7. PubMed ID: 22440044
[TBL] [Abstract][Full Text] [Related]
10. Nephroprotection with saxagliptin.
Iazzetta N; Garofalo C; Savino M; Sagliocca A; Santangelo S; Pacilio M; Liberti ME; Camocardi A; Ambrosca C; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2015; 32(6):. PubMed ID: 26845214
[TBL] [Abstract][Full Text] [Related]
11. Glomerular and tubular damage markers are elevated in patients with diabetes.
Nauta FL; Boertien WE; Bakker SJ; van Goor H; van Oeveren W; de Jong PE; Bilo H; Gansevoort RT
Diabetes Care; 2011 Apr; 34(4):975-81. PubMed ID: 21307379
[TBL] [Abstract][Full Text] [Related]
12. Association of urinary liver-type fatty acid-binding protein with renal functions and antihyperglycemic drug use in type 2 diabetic nephropathy patients.
Hirowatari K; Kawano N
Int Urol Nephrol; 2023 Aug; 55(8):2111-2118. PubMed ID: 36840803
[TBL] [Abstract][Full Text] [Related]
13. Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus.
Kim SS; Song SH; Kim JH; Jeon YK; Kim BH; Kang MC; Chun SW; Hong SH; Chung M; Kim YK; Kim IJ; Kim YB
Clin Endocrinol (Oxf); 2017 Aug; 87(2):156-164. PubMed ID: 28434209
[TBL] [Abstract][Full Text] [Related]
14. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
15. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes.
de Carvalho JA; Tatsch E; Hausen BS; Bollick YS; Moretto MB; Duarte T; Duarte MM; Londero SW; Premaor MO; Comim FV; Delanghe JR; Moresco RN
Clin Biochem; 2016 Feb; 49(3):232-6. PubMed ID: 26519090
[TBL] [Abstract][Full Text] [Related]
16. Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.
Gangadharan Komala M; Gross S; Zaky A; Pollock C; Panchapakesan U
Nephrology (Carlton); 2016 May; 21(5):423-31. PubMed ID: 26375854
[TBL] [Abstract][Full Text] [Related]
17. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
[TBL] [Abstract][Full Text] [Related]
18. Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes.
Żyłka A; Gala-Błądzińska A; Dumnicka P; Ceranowicz P; Kuźniewski M; Gil K; Olszanecki R; Kuśnierz-Cabala B
Dis Markers; 2016; 2016():8489543. PubMed ID: 28050059
[No Abstract] [Full Text] [Related]
19. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes.
Xie Y; Xue W; Shao X; Che X; Xu W; Ni Z; Mou S
PLoS One; 2014; 9(11):e112865. PubMed ID: 25402279
[TBL] [Abstract][Full Text] [Related]
20. Plasma Neutrophil Gelatinase-Associated Lipocalin as a Marker of Tubular Damage in Diabetic Nephropathy.
Kim SY; Jeong TD; Lee W; Chun S; Sunwoo S; Kim SB; Min WK
Ann Lab Med; 2018 Nov; 38(6):524-529. PubMed ID: 30027695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
